INHIBITION OF CSF1R-CSF1 AXIS WITH AXATILIMAB EFFECTIVELY TARGETS LEUKEMIA STEM CELLS AND MONOCYTES IN BH3 MIMETICS-RESISTANT AML

EHA Library, Bing Carter, 4159816

A NOVEL ROLE FOR TRANSCRIPTION FACTOR NFE2 IN REGULATING REDOX RESPONSES AND CHEMOTHERAPY RESISTANCE IN ACUTE MYELOID LEUKEMIA

EHA Library, Anne Marie Staehle, 4159817

PROTEIN S-ACYLATION DYNAMICS PROVIDE METABOLIC FLEXIBILITY TO ACUTE MYELOID LEUKEMIA CELLS

EHA Library, Nick van Gastel, 4159818

REM-422, A SMALL MOLECULE MYB MRNA DEGRADER, DEMONSTRATES ANTI-LEUKEMIC ACTIVITY AS A MONOTHERAPY AND IN COMBINATION WITH STANDARDS OF CARE IN PRECLINICAL MODELS OF AML

EHA Library, Charles Kung, 4159819

THE GLYCOSYLTRANSFERASE MGAT1 IS A VULNERABILITY IN AML IN VITRO AND IN VIVO AND ALTERS THE AFFINITIES OF ANTI-EPITOPE DIRECTED IMMUNOTHERAPIES

EHA Library, Cosima Nather, 4159820

TARGETING ZEB1 TO ENHANCE MENIN-INHIBITOR SENSITIVITY IN KMT2A-MLLT3 ACUTE MYELOID LEUKEMIA THROUGH MODULATION OF MICRORNA-204

EHA Library, Liam MacPhee, 4159821

OVERCOMING VENETOCLAX RESISTANCE: SYNERGISTIC POTENTIAL OF RVU120, A CDK8/CDK19 INHIBITOR, IN COMBINATION TREATMENT.

EHA Library, Urszula Pakulska, 4159822

MULTIMODAL MACHINE LEARNING DECODES TRANSCRIPTION FACTORS-DRIVEN NK CELL DYSFUNCTION IN AML: A SINGLE-CELL TRANSCRIPTOMIC ROADMAP FOR PRECISION IMMUNOTHERAPY

EHA Library, jiaxiu Ma, 4159823

VENETOCLAX 50 MG WITH AZOLE VS. 400 MG WITHOUT AZOLE: COMPARABLE CLINICAL EFFICACY DESPITE LOWER DRUG EXPOSURE PROFILES—A PROSPECTIVE STUDY ON PHARMACOKINETICS, EFFICACY, AND TOXICITY IN NEWLY DIAGNOSED AML PATIENTS

EHA Library, Rudra narayan Swain, 4159824

LOW-TOXICITY ANTIBODY DRUG-CONJUGATE THERAPY FOR AML PATIENTS TARGETING THE GLYCOSAMINOGLYCAN ONCOFETAL CHONDROITIN SULFATE

EHA Library, Priya Khadgawat, 4159825

HARNESSING ENGINEERED INVARIANT NATURAL KILLER T CELLS (INKT CELLS) AGAINST CD117: A NOVEL STRATEGY FOR TREATING ACUTE MYELOID LEUKEMIA

EHA Library, chaiyaporn boonchalermvichian, 4159826

GLYCOLYSIS-DRIVEN IMMUNE EVASION IN ACUTE MYELOID LEUKEMIA IMPAIRS MACROPHAGE-MEDIATED CLEARANCE

EHA Library, Isabel Weinhauser, 4159827

COMPUTATIONAL MEASURABLE RESIDUAL DISEASE ASSESSMENT IMPROVES RELAPSE PREDICTION IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE VALIDATION IN THE HOVON-SAKK-132 TRIAL

EHA Library, Tim Mocking, 4159828

TARGETING MUTANT ISOCITRATE DEHYDROGENASE THROUGH FRUCTOSE METABOLISM

EHA Library, Angela Maria Savino, 4159829

KMT2E EXPRESSION DEFINES A SUBSET OF LEUKEMIC STEM CELLS WITH OXPHOS DEPENDENCE AND THERAPEUTIC SENSITIVITY TO RETINOIC ACID AND PARP1 INHIBITION

EHA Library, Luise A de A Simoes, 4159830

OVERCOMING VENETOCLAX RESISTANCE BY SELECTIVE PARP1 INHIBITION IN ACUTE MYELOID LEUKEMIA

EHA Library, Justinas Daraskevicius, 4159831

PRL2 IS ESSENTIAL FOR THE MAINTENANCE OF LEUKEMIA STEM CELL IN MLL GENE REARRANGEMENT ACUTE MYELOID LEUKEMIA VIA INTERACTING WITH KDM2B

EHA Library, Hongxia Chen, 4159832

REFINING AML PATIENTS' KARYOTYPES USING OPTICAL GENOME MAPPING. UNRAVELING CRYPTIC ALTERATIONS AND DECIPHERING COMPLEX KARYOTYPES.

EHA Library, Neus Torres Hernández, 4159833

SORAFENIB REVERSES VENETOCLAX SECONDARY RESISTANCE IN ACUTE MYELOID LEUKAEMIA VIA DOWNREGULATION OF THE RAS-RAF-MEK-ERK SIGNALLING PATHWAY

EHA Library, zhangbiao long, 4159835

LEVELS OF 91 CIRCULATING INFLAMMATORY PROTEINS AND RISK OF ACUTE MYELOID LEUKEMIA : A MENDELIAN RANDOMIZATION STUDY

EHA Library, Tao Wu, 4159836

CD39 EXPRESSION ON AML BLASTS INFLUENCES TH1 CELL DIFFERENTIATION AND PROLIFERATION VIA WNT6 AND SPP1-CD44 SIGNALING PATHWAYS WITHIN THE BONE MARROW MICROENVIRONMENT

EHA Library, Hanheng Mai, 4159837

MESENCHYMAL STROMAL CELLSPROTECT ACUTE MYELOID LEUKAEMIA CELLS FROM VENETOCLAX-INDUCED APOPTOSIS THROUGH A CD90-MEDIATED ADHESION PATHWAY

EHA Library, Karyna Volkava, 4159838

MOLECULAR PROFILING OF PEDIATRIC AML: A NEXT-GENERATION SEQUENCING APPROACH IN A SINGLE-CENTER COHORT

EHA Library, Alba Crespo-Carrasco, 4159839

INTRACELLULAR SIGNALING SIGNATURES IN THE MONOCYTIC COMPARTMENT DISTINGUISH ACUTE MYELOID LEUKEMIA FROM HEALTHY PERIPHERAL BLOOD AND BONE MARROW

EHA Library, Oriol Castells, 4159840

LONG-READ SEQUENCING REVEALS THE LANDSCAPE OF ABERRANT SPLICING IN DDX41 MUTATED AML

EHA Library, Carolin Seeling, 4159841

PROTEIN ARGININE METHYLTRANSFERASE (PRMT2) IS INVOLVED IN JNK SIGNALING AND CYTOSKELETON REORGANIZATION BY COOPERATING WITH VAV1 AND WASP/WIPF1 IN ACUTE MYELOBLASTIC LEUKEMIA

EHA Library, Denis Masnikov, 4159842

TP53-MUTATED AML: A MULTI-OMICS APPROACH TO UNDERSTAND HETEROGENEITY AND THERAPEUTIC VULNERABILITIES

EHA Library, Ana RIO-MACHIN, 4159843

GENOMIC AND TRANSCRIPTOMIC DETERMINANTS ON CLINICAL OUTCOME IN AML PATIENTS WITH DNMT3A MUTATION

EHA Library, Feng-Ming Tien, 4159844

IDENTIFICATION OF NOVEL HIGH-RISK SUBTYPES BY DEVELOPMENT OF MULTI-OMICS-BASED MOLECULAR CLASSIFICATION TO GUIDE PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA

EHA Library, Runyu Yang, 4159845

SINGLE CELL SEQUENCING DECIPHERING THE HETEROGENEOUS LANDSCAPE OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM WITH NOVEL MYB-ZFAT FUSION GENE

EHA Library, Ruijuan Li, 4159846

IDH1/2-MUTATED AML: MOLECULAR PROFILE AND PROGNOSTIC IMPACT OF IDH1/2-MRD IN IDH1/2-MUTATED AML FROM THE FRENCH HAUTS-DE-FRANCE AML OBSERVATORY

EHA Library, Mélinda Dantec, 4159847

WOGONIN INDUCES APOPTOTIC CELL DEATH THROUGH PI3K/AKT AND MAPK/ ERK PATHWAYS AND SYNERGIZES WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA

EHA Library, Xia Jiang, 4159848

VENETOCLAX SYNERGIZES WITH HK2 INHIBITOR 2 - DG IN ACUTE MYELOID LEUKEMIA VIA THE ENDOPLASMIC RETICULUM STRESS PATHWAY.

EHA Library, Menghua Sun, 4159849

FLT3 MUTATION DRIVES THE IMMUNOPHENOTYPIC SIGNATURE OF LEUKEMIC DIFFERENTIATION ARREST AND ALTERS NK CELL PROFILE IN ACUTE MYELOID LEUKEMIA

EHA Library, Allana Carvalho, 4159851

IN DEPTH CHARACTERIZATION OF COMPLEX KARYOTYPE ACUTE MYELOID LEUKEMIA (CKAML) WITH 5Q DELETIONS USING LONG READ SEQUENCING TECHNOLOGIES

EHA Library, Anna Dolnik, 4159852

DECIPHERING CLONAL HETEROGENEITY IN AML NPM1 THROUGH SINGLE-CELL MULTI-OMIC

EHA Library, Wencke Walter, 4159854

ISOVALERYLSPIRAMYCIN I SUPPRESSES THE PROLIFERATION OF MYELOID MALIGNANCIES VIA NLRP3 INFLAMMASOME-MEDIATED PYROPTOSIS AND ROS-DRIVEN DNA DAMAGE RESPONSE.

EHA Library, wenbin yang, 4159855

IDENTIFICATION OF LEUKEMIC STEM CELLS IN AML PATIENTS BY USING NEXT-GENERATION FLOW (NGF): A PERSONALIZED BIOMARKER OF PROGNOSIS AND PROGRESSION

EHA Library, Anna Sicuranza, 4159856

NGS-DRIVEN DIGITAL PCR: A HIGHLY SENSITIVE AND EFFECTIVE TOOL FOR MONITORING MEASURABLE RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA.

EHA Library, Mirko Farina, 4159857

CD52 PROMOTER METHYLATION PREDICTS RESPONSE TO AKT-TARGETING DRUGS IN ACUTE MYELOID LEUKEMIA

EHA Library, Carlos Quero-Dotor, 4159858

THE MOLECULAR BACKGROUND DETERMINES THE EXTENT BY WHICH LSD1 INHIBITORS SENSITIZE AML CELLS TO KINASE AND RAS INHIBITORS

EHA Library, Pedro Casado, 4159859

THE MECHANISM AND THERAPEUTIC SIGNIFICANCE OF THE HO-1/MPO AXIS IN DRIVING IMMUNE EVASION OF ACUTE MYELOID LEUKEMIA THROUGH REPROGRAMMING TUMOR-ASSOCIATED MACROPHAGE POLARIZATION

EHA Library, Jishi Wang, 4159860

OVERCOMING CHEMOTHERAPY RESISTANCE THROUGH TARGETED INHIBITION OF DNA-PK-DEPENDENT DNA REPAIR.

EHA Library, shuyu Qin, 4159861

SELINEXOR MODULATES T CELL FUNCTION AND ALLEVIATES GVHD WHILE INHIBITING AML CELL PROLIFERATION

EHA Library, Xiwen Tong, 4159862

DRUG SCREENING IN A ZEBRAFISH MODEL OF MLL-AF9-DRIVEN ACUTE MYELOID LEUKEMIA

EHA Library, Maryam Saberi, 4159863

EPIDEMIOLOGY, CLINICAL FEATURES, AND MOLECULAR BASIS OF TTMV::RARA-DRIVEN ACUTE PROMYELOCYTIC LEUKEMIA

EHA Library, Xiaosu Zhou, 4159864

TARGETING RIBOFLAVIN METABOLISM IN ACUTE MYELOID LEUKEMIA

EHA Library, Stefan Bjelosevic, 4159865

DEVELOPMENT OF A DUAL TARGETING CD123-CD33 CAR-T CELL THERAPY AS A BRIDGE TO ALLO-HSCT IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Vladimir Mulens-Arias, 4159866

TONIC INTERFERON SIGNALING IN ACUTE MYELOID LEUKEMIA CELLS IS ASSOCIATED WITH ADVERSE DISEASE OUTCOME

EHA Library, Sophie Edtmayer, 4159867

COMPENSATORY KDM4 UPREGULATION IN IDH2-MUTANT AMLS REPRESENTS A THERAPEUTIC VULNERABILITY IN ENASIDENIB-SENSITIVE PATIENTS

EHA Library, Dominique Sternadt, 4159868

SYNERGISTIC EFFICACY OF HDACI CHIDAMIDE WITH GL-V9 BY SUPPRESSING MYBL2 EXPRESSION IN ACUTE MYELOID LEUKEMIA

EHA Library, Zheng Ge, 4159869

LIPOSOMAL MITOXANTRONE DEMONSTRATES SUPERIORITY TO TRADITIONAL MITOXANTRONE IN THE TREATMENT OF AML: DUAL MECHANISMS OF INDUCING APOPTOSIS AND BOOSTING IMMUNE RESPONSE

EHA Library, Wenqiang Qu, 4159870

FERROPTOSIS SENSITIVITY IN ACUTE MYELOID LEUKEMIA OPENS AVENUES FOR THE DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES

EHA Library, Yara Lackousha, 4159871

LONG-TERM SURVIVAL FOR MYELOID NEOPLASMS AND NATIONAL HEALTH EXPENDITURE: A EUROCARE-6 RETROSPECTIVE, POPULATION-BASED STUDY

EHA Library, Claudia Vener, 4159872

MONITORING OF (LEUKEMIA-SPECIFIC) IMMUNE CELLS IN STAGES, TREATMENT GROUPS AND IN THE COURSE OF DISEASE AND THERAPY CONTRIBUTES TO QUANTIFY ANTILEUKEMIC POTENTIAL AND SURVIVAL IN PATIENTS WITH AML.

EHA Library, Helga Schmetzer, 4159873

CDK6 INHIBITION COUPLED WITH VITAMIN D RECEPTOR ACTIVATION SYNERGISTICALLY PROMOTES AML DIFFERENTIATION AND CELL DEATH.

EHA Library, Antonia Boudet, 4159874

VALIDATION OF A 4-GENE PROGNOSTIC INDEX IN A REAL-WORLD BRAZILIAN COHORT AND EVALUATION OF PHARMACOLOGICAL INHIBITION TO ENHANCE CHEMOTHERAPY RESPONSE IN ACUTE MYELOID LEUKEMIA

EHA Library, Maria Luiza Salustiano-Bandeira, 4159875

NOVEL THERAPEUTIC TARGETS FOR ACUTE MYELOID LEUKEMIA IDENTIFIED THROUGH MULTICENTER PROTEOME-WIDE MENDELIAN RANDOMIZATION

EHA Library, Linhui Hu, 4159876

TRANSCRIPTOMICS OF NUCLEAR FACTOR IA-MEDIATED AML LEUKEMOGENESIS UNVEIL NOVEL TARGETS FOR AML THERAPY

EHA Library, Jan-Henrik Mikesch, 4159877

THE SYNERGY OF DZNEP WITH CX-4945 AND THE CLINICAL RELEVANCE OF FOSL1 IN ACUTE MYELOID LEUKEMIA

EHA Library, Zheng Ge, 4159878

COMPREHENSIVE CHARACTERIZATION OF THE BONE MARROW MICROENVIRONMENT IDENTIFIES A DISTINCT IMMUNE SIGNATURE ASSOCIATED WITH TUMOR BURDEN IN ACUTE MYELOID LEUKEMIA

EHA Library, Nicole Fincato, 4159879

ZIFTOMENIB IN RELAPSED/REFRACTORY NPM1-MUTANT ACUTE MYELOID LEUKEMIA: PHASE 1B/2 CLINICAL ACTIVITY AND SAFETY RESULTS FROM THE PIVOTAL KOMET-001 STUDY

EHA Library, Amir Fathi, 4159880

LONG-TERM REAL-WORLD EXPERIENCE WITH CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND

EHA Library, Alexandrina Lambova, 4159881

AZACITIDINE IN COMBINATION WITH REDUCED DURATION VENETOCLAX IN PATIENTS WITH DE NOVO, SECONDARY, AND RELAPSE/REFRACTORY ACUTE MYELOID LEUKEMIA: INTERIM ANALYSIS OF THE PROSPECTIVE NAMLG LD-VENEX TRIAL

EHA Library, Anne Louise Tølbøll Sørensen, 4159882

UPDATED RESULTS FROM THE ONGOING PHASE 1/2A STUDY OF MP0533, A TETRA-SPECIFIC DESIGNED ANKYRIN REPEAT PROTEIN (DARPIN; CD33 X CD123 X CD70 X CD3), IN PATIENTS WITH RELAPSED/REFRACTORY AML OR MDS/AML

EHA Library, Pierre Bories, 4159883

UPDATED SAFETY & ANTILEUKEMIC ACTIVITY DATA OF SONROTOCLAX (BGB-11417), A POTENT AND SELECTIVE BCL2 INHIBITOR, IN TREATMENT-NAIVE PATIENTS WITH ACUTE MYELOID LEUKEMIA UNFIT FOR INTENSIVE CHEMOTHERAPY

EHA Library, Jake Shortt, 4159884

TRANSCRIPTOMICALLY-REFINED ACUTE MYELOID LEUKEMIA, MYELODYSPLASIA-RELATED (AML-MR) REFINES SURVIVAL ASSOCIATIONS AND PRESENTS WITH DISTINCT BIOLOGICAL FEATURES

EHA Library, Lorenz Oelschlaeger, 4159885

CPX-351 IN PATIENTS WITH NEWLY DIAGNOSED POST MYELOPROLIFERATIVE NEOPLASMS ACUTE MYELOID LEUKEMIA . FINAL RESULTS OF THE CPX-TA SMP PHASE II TRIAL.

EHA Library, Sylvain Garciaz, 4159886

FINAL RESULTS OF VEN A QUI TRIAL: A PHASE I-II TRIAL COMPARING VENETOCLAX WITH LOW DOSE CYTARABINE OR AZACITIDINE COMBINED WITH QUIZATINIB IN NON-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Juan Miguel Bergua Burgues, 4159887

REAL-LIFE OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO MYELOPROLIFERATIVE NEOPLASIA: RESULTS OF MULTICENTRIC ENEA-STUDY.

EHA Library, Giulia Ciotti, 4159888

CONDITIONING INTENSITY, CONCURRENT NPM1 MUTATIONS, AND MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH FLT3-ITD AML UNDERGOING ALLOGENEIC TRANSPLANTATION: A POST-HOC ANALYSIS FROM BMT CTN 1506

EHA Library, Mark Levis, 4159889

CLONAL ORIGIN AND EVOLUTION PATTERN UNDERLIE THE HETEROGENEITY OF FLT3-ITD-POSITIVE ACUTE MYELOID LEUKEMIA

EHA Library, Anli Lai, 4159890

STANDARD CHEMOTHERAPY AS FIRST LINE TREATMENT FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS (BPDCN) IN THE ERA OF CD123 TRAGETED THERAPIES: FINAL RESULTS OF A FRENCH PROSPECTIVE TRIAL

EHA Library, Eric Deconinck, 4159891

THE COMBINATION OF VENETOCLAX AND AZACITIDINE IS ASSOCIATED WITH A REDUCED RISK OF INFECTIOUS EVENTS COMPARED TO INTENSIVE CHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY AML. A RETROSPECTIVE STUDY BY THE FHU GOAL

EHA Library, Bobo Maxime, 4159892

TIME TO TREATMENT INITIATION AND CLINICAL OUTCOMES IN NON-INTENSIVELY TREATED ADULT ACUTE MYELOID LEUKEMIA: A PETHEMA-GPLA-ACHO-GRELAM REGISTRY STUDY

EHA Library, Eduardo Rodríguez-Arbolí, 4159893

VALIDATION OF GENETIC RISK CLASSIFICATION ELN 2024 IN REAL-WORLD AML PATIENTS TREATED WITH HMA AND HMA/VEN BASED REGIMENS

EHA Library, Juan Miguel Bergua Burgues, 4159894

MRD IN ACUTE MYELOID LEUKEMIA: A BABYLONIAN MISCOMMUNICATION?

EHA Library, Gwendolyn Van Gorkom, 4159895

VENETOCLAX PLUS IDARUBICIN AND CYTARABINE TREATMENT AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PEDIATRIC ACUTE MYELOID LEUKEMIA

EHA Library, shiyuan wang, 4159896

PROGNOSTIC IMPACT OF GERIATRIC ASSESSMENT IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH AZACITIDINE-VENETOCLAX

EHA Library, Marie Adeline Migeon, 4159897

UPDATED SAFETY AND ANTILEUKEMIC ACTIVITY DATA FOR SONROTOCLAX (BGB-11417), A POTENT AND SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Pau Montesinos, 4159898

EVOLUTION OF REAL-WORLD TREATMENT PATHWAYS FOR SECONDARY ACUTE MYELOID LEUKEMIA IN ENGLAND

EHA Library, Alexandrina Lambova, 4159899

PHASE 1/1B TRIAL OF TALAZOPARIB AND GEMTUZUMAB OZOGAMICIN IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD33+ ACUTE MYELOID LEUKEMIA

EHA Library, Ross McCauley, 4159900

CLINICAL IMPLICATIONS AND MOLECULAR PROFILING REVEAL AN APL-LIKE SUBGROUP OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Mingkai Shu, 4159901

OUTCOMES OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA AFTER MENIN INHIBITION

EHA Library, Kuo-Kai Chin, 4159902

EXPLORING OPTIMIZATION STRATEGIES BASED ON CD123 CAR-NK CLINICAL TRIAL RESULTS IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Anqi Zhang, 4159903

PROGNOSTIC VALUE OF MEASURABLE RESIDUAL MUTATED IDH2 IN INTENSIVELY TREATED AML PATIENTS DEPENDS ON THE MEASURED TIME POINT

EHA Library, Lena Cimbalnik, 4159904

REVISITING TIME TO TREATMENT INITIATION AND CLINICAL OUTCOMES IN INTENSIVELY TREATED ADULT ACUTE MYELOID LEUKEMIA: INSIGHTS FROM THE PETHEMA-GPLA-ACHO-GRELAM REGISTRY

EHA Library, Eduardo Rodríguez-Arbolí, 4159905

ODYSSEY: A FIRST-IN-HUMAN STUDY OF FIRST-IN-CLASS INHIBITOR OF ALDEHYDE DEHYDROGENASE (ALDH), ABD-3001, IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

EHA Library, Régis Costello, 4159906

REAL-WORLD UTILIZATION, SAFETY, AND CLINICAL OUTCOMES WITH GEMTUZUMAB OZOGAMICIN (GO) IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Elizabeth Herrity, 4159907

IMPACT OF VENETOCLAX PEAK CONCENTRATIONS ON TREATMENT EFFICACY IN ACUTE MYELOID LEUKEMIA (AML)

EHA Library, mengyun zhang, 4159908

THE EFFICACY AND SAFETY OF LUVOMETINIB (FCN-159) IN PEDIATRIC PATIENTS WITH REFRACTORY/RELAPSED LANGERHANS CELL HISTIOCYTOSIS: A MULTI-CENTER, OPEN-LABEL, SINGLE-ARM PHASE II STUDY

EHA Library, Rui Zhang, 4159909

DO APL PATIENTS TREATED WITH ATO+ATRA ACHIEVE A NORMAL LIFE EXPECTANCY? INSIGHTS FROM THE LONG TERM FOLLOW-UP OF THE GIMEMA APL0406 STUDY

EHA Library, Alfonso Piciocchi, 4159910

A PHASE 1B STUDY OF NAVTEMADLIN IN COMBINATION WITH DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA

EHA Library, Homa Dadrastoussi, 4159911

RAPID EVALUATION OF BCL2 FAMILY RNA EXPRESSION PREDICTS SURVIVAL ACROSS GENETIC SUBGROUPS OF AML PATIENTS TREATED WITH HYPOMETHYLATING AGENTS COMBINED WITH VENETOCLAX

EHA Library, Curtis Lachowiez, 4159912

PRELIMINARY SAFETY, PHARMACOKINETIC, AND CLINICAL ACTIVITY RESULTS WITH FHD-286, A BRG1/BRM INHIBITOR, PLUS DECITABINE IN A PHASE 1 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY MYELOID MALIGNANCIES

EHA Library, Courtney DiNardo, 4159913

PROGNOSTIC SIGNIFICANCE OF CLONAL MONITORING ASSESSED BY VAF IN UNFIT NEWLY DIAGNOSED AML: INSIGHTS FROM THE PETHEMA VEN-A-QUI TRIAL

EHA Library, Alba Mora, 4159914

EVALUATION OF IMMUNOPHENOTYPICAL MARKERS FOR LEUKEMIC STEM CELL AND ITS PROGNOSTIC VALUE IN ACUTE MYELOID LEUKEMIA: A PROSPECTIVE STUDY

EHA Library, Hongyan Liao, 4159915

KMT2A REARRANGEMENTS IN PEDIATRIC INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA: FUSION PARTNER IMPACT AND PROGNOSTIC INSIGHTS. A COMPREHENSIVE SURVIVAL ANALYSIS

EHA Library, Hend Ali, 4159916

SURVIVAL TRENDS IN HODGKIN LYMPHOMA (HL) FROM 1980 TO 2020: EXPERIENCE FROM A REFERRAL CENTER

EHA Library, Theodoros Vassilakopoulos, 4160281

LONGITUDINAL TARGETED CTDNA ANALYSIS TO ASSESS CD20 AND BAFF MUTATIONS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FL OR DLBCL PROGRESSING ON ODRONEXTAMAB TREATMENT IN THE ELM-2 STUDY

EHA Library, Stefano Luminari, 4160405